(Q36822438)

16 August 2017

1 reference

title

Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy (English)

1 reference

Rosario Vincenzo Iaffaioli

16 August 2017

author

series ordinal

3

object named as

Rosario Vincenzo Iaffaioli

1 reference

16 August 2017

Amalia Milano

1

1 reference

16 August 2017

Vincenzo De Rosa

series ordinal

2

1 reference

16 August 2017

Francesco Caponigro

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Therapeutic Targets

16 August 2017

published in

1 reference

16 August 2017

volume

11

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

771-782

1 reference

Untangling the ErbB signalling network

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Signal perception and transduction: the role of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Src activation regulates anoikis in human colon tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Ubiquitination regulates PTEN nuclear import and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The extended protein kinase C superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Inactivation of Bcl-2 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Platelet-derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.6.771

10.1517/14728222.11.6.771

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference